By B.N. Frank
Some experts have testified that the U.S. COVID death count is not being accurately reported. Additionally, members of the Amish community claimed they obtained “herd immunity” the natural way last year. Nevertheless, vaccine proponents still encourage penalizing the vaccine hesitant despite side effects, injuries, and deaths attributed to the COVID jab (see 1, 2, 3, 4). Also troubling, a significant number of people who have taken the jab are still getting COVID.
The good news is that an inexpensive drug may work wonders for those stricken, as well as long haulers.
More from NBC News:
Cheap antidepressant shows promise treating early Covid
The $4 pill, called fluvoxamine, reduced the need for hospitalization among high-risk adults, according researchers.
Oct. 27, 2021, 8:51 PM EDT / Source: Associated Press
By The Associated Press
A cheap antidepressant reduced the need for hospitalization among high-risk adults with Covid-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.
Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies.
They’ve shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation.
“If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available. “We hope it will lead to a lot of lives saved.”
The pill, called fluvoxamine, would cost $4 for a course of Covid treatment. By comparison, antibody IV treatments cost about $2,000 and Merck’s experimental antiviral pill for Covid is about $700 per course. Some experts predict various treatments eventually will be used in combination to fight the coronavirus.
Activist Post reports regularly about COVID-19, as well as opposition to medical mandates. For more information visit our archives.
Provide, Protect and Profit from what’s coming! Get a free issue of Counter Markets today.